NDLI: Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12

Content Provider	PubMed Central
Author	Zheng, Rongxiu Cohen, Peter A. Paustian, Christopher A. Johnson, Terrence D. Lee, Walter T. Shu, Suyu Koski, Gary K.
Abstract	Minimal requirements for generating effective immunity include the delivery of antigenic (signal 1) and costimulatory (signal 2) signals to T lymphocytes. Recently, a class of 3rd signals, often delivered by antigen-presenting dendritic cells, has been shown greatly to enhance immune responses, especially against tumors. Among signal 3 factors, interleukin-12 is particularly effective and can be conditionally induced by agonists of Toll-like transmembrane receptors (TLRs). In this study, we assessed the therapeutic impact of adjuvant TLR agonist administration upon the capacity of DC-tumor electrofusion hybrids to eradicate established MCA-205 sarcomas in syngeneic mice. Paired, but not solitary combinations of polyinosine:polycytadilic acid (p[I:C], TLR3 agonist) and CpG DNA (ODN1826, TLR9 agonist) stimulated IL-12 secretion from DCs in vitro and synergized with vaccination to achieve potent tumor rejection. Therapeutic effects, however, required co-administration of paired TLR agonists and DC-tumor fusion hybrids. The administration of TLR agonists alone or with fusion vaccine induced transient splenomegaly, but without apparent toxicity. The therapeutic effects of this immunization regimen were significantly abrogated through the neutralization of IL-12p70, indicating that production of this 3rd signal was essential to the observed tumor regression. These results demonstrate the profound functional consequences of TLR cooperativity and further highlight the critical role of IL-12 in anti-tumor immunity.
Related Links	http://dx.doi.org/10.1158/0008-5472.can-07-6669
Ending Page	4049
Page Count	5
Starting Page	4045
File Format	PDF
ISSN	00085472
e-ISSN	15387445
Journal	Cancer research
Issue Number	11
Volume Number	68
Language	English
Publisher Date	2008-06-01
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Toll-like receptor agonists in cancer therapy

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Toll-like receptor agonists: are they good adjuvants?

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Systemic cancer immunotherapy with Toll-like receptor 7 agonists

The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy.

Activation of NF-kB by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4

Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12

Similar Documents

Toll-like receptor agonists in cancer therapy

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Toll-like receptor agonists: are they good adjuvants?

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling

Systemic cancer immunotherapy with Toll-like receptor 7 agonists

The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy.

Activation of NF-kB by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4

Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12